Published in J Antimicrob Chemother on June 11, 2010
Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia. J Clin Microbiol (2013) 1.20
Monitoring HIV viral load in resource limited settings: still a matter of debate? PLoS One (2012) 1.12
A simple method to quantitate IP-10 in dried blood and plasma spots. PLoS One (2012) 0.95
Prospective evaluation of diagnostic accuracy of dried blood spots from finger prick samples for determination of HIV-1 load with the NucliSENS Easy-Q HIV-1 version 2.0 assay in Malawi. J Clin Microbiol (2014) 0.94
Higher specificity of nucleic acid sequence-based amplification isothermal technology than of real-time PCR for quantification of HIV-1 RNA on dried blood spots. J Clin Microbiol (2013) 0.92
Identification and molecular characterization of new simian T cell lymphotropic viruses in nonhuman primates bushmeat from the Democratic Republic of Congo. AIDS Res Hum Retroviruses (2011) 0.91
Implementation and Operational Research: Programmatic Feasibility of Dried Blood Spots for the Virological Follow-up of Patients on Antiretroviral Treatment in Nord Kivu, Democratic Republic of the Congo. J Acquir Immune Defic Syndr (2016) 0.88
Field study of dried blood spot specimens for HIV-1 drug resistance genotyping. J Clin Microbiol (2014) 0.87
Comparison of Ahlstrom grade 226, Munktell TFN, and Whatman 903 filter papers for dried blood spot specimen collection and subsequent HIV-1 load and drug resistance genotyping analysis. J Clin Microbiol (2012) 0.86
Single real-time reverse transcription-PCR assay for detection and quantification of genetically diverse HIV-1, SIVcpz, and SIVgor strains. J Clin Microbiol (2012) 0.82
Antiretroviral treatment outcome in HIV-1-infected patients routinely followed up in capital cities and remote areas of Senegal, Mali and Guinea-Conakry. J Int AIDS Soc (2014) 0.81
Evaluation of Two Techniques for Viral Load Monitoring Using Dried Blood Spot in Routine Practice in Vietnam (French National Agency for AIDS and Hepatitis Research 12338). Open Forum Infect Dis (2016) 0.77
Pyrosequencing dried blood spots reveals differences in HIV drug resistance between treatment naïve and experienced patients. PLoS One (2013) 0.77
Stability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance Genotyping. PLoS One (2015) 0.76
Dried blood spot testing: filling the gap between antiretroviral treatment & monitoring in India. Indian J Med Res (2012) 0.75
Use of Dried Plasma Spots for HIV-1 Viral Load Determination and Drug Resistance Genotyping in Mexican Patients. Biomed Res Int (2015) 0.75
Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes. Pathog Immun (2016) 0.75
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12
Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS (2006) 6.46
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet (2004) 4.81
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature (2010) 4.35
Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13
The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS (2002) 4.01
Evolutionary relationships of wild hominids recapitulated by gut microbial communities. PLoS Biol (2010) 4.01
Hybrid origin of SIV in chimpanzees. Science (2003) 3.75
Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe (2009) 3.58
Human immunodeficiency viruses: SIV infection in wild gorillas. Nature (2006) 3.35
Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS (2003) 3.14
Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr (2005) 3.09
Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis (2002) 2.98
Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis (2011) 2.82
Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr (2007) 2.72
Multiple diverse circoviruses infect farm animals and are commonly found in human and chimpanzee feces. J Virol (2009) 2.70
African great apes are natural hosts of multiple related malaria species, including Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 2.60
Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis (2013) 2.53
Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis (2013) 2.51
Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology (2007) 2.01
Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS (2003) 1.94
Molecular ecology and natural history of simian foamy virus infection in wild-living chimpanzees. PLoS Pathog (2008) 1.92
A plethora of Plasmodium species in wild apes: a source of human infection? Trends Parasitol (2011) 1.78
Adaptation of HIV-1 to its human host. Mol Biol Evol (2007) 1.77
Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J Virol (2008) 1.76
Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form. J Virol (2007) 1.74
Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis (2005) 1.73
Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir Ther (2013) 1.68
New simian immunodeficiency virus infecting De Brazza's monkeys (Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade. J Virol (2004) 1.68
Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol (2009) 1.65
Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol (2003) 1.61
Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS (2003) 1.61
Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol (2007) 1.58
Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS (2011) 1.55
Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr (2002) 1.51
Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. Am J Trop Med Hyg (2006) 1.48
Novel circular DNA viruses in stool samples of wild-living chimpanzees. J Gen Virol (2009) 1.46
Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One (2009) 1.43
Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas. J Virol (2009) 1.42
Widespread infection with homologues of human parvoviruses B19, PARV4, and human bocavirus of chimpanzees and gorillas in the wild. J Virol (2010) 1.42
Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther (2009) 1.35
Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002. J Acquir Immune Defic Syndr (2005) 1.34
The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology (2006) 1.33
Simian T-cell leukemia virus (STLV) infection in wild primate populations in Cameroon: evidence for dual STLV type 1 and type 3 infection in agile mangabeys (Cercocebus agilis). J Virol (2004) 1.30
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther (2005) 1.30
The origins of HIV and implications for the global epidemic. Curr Infect Dis Rep (2007) 1.29
Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses (2009) 1.25
Anthrax in Western and Central African great apes. Am J Primatol (2006) 1.24
Detection and genetic characterization of enteroviruses circulating among wild populations of chimpanzees in Cameroon: relationship with human and simian enteroviruses. J Virol (2011) 1.23
Cross-species transmission of simian retroviruses: how and why they could lead to the emergence of new diseases in the human population. AIDS (2012) 1.23
High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo. J Int AIDS Soc (2011) 1.21
Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon context: promoting the use of medication reminder methods. J Acquir Immune Defic Syndr (2011) 1.21
CRF06-cpx: a new circulating recombinant form of HIV-1 in West Africa involving subtypes A, G, K, and J. J Acquir Immune Defic Syndr (2002) 1.21
Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. Infect Genet Evol (2009) 1.20
Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia. J Clin Microbiol (2013) 1.20
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses (2008) 1.19
Sympatric chimpanzees and gorillas harbor convergent gut microbial communities. Genome Res (2013) 1.19
Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis. J Acquir Immune Defic Syndr (2011) 1.19